In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Pregabalina Tarbis
It is essential to take the Pregabalina capsules regularly at the same hour every day. If you forget to take a dose, take it as soon as you remember, unless it is time for the next dose. In that case, continue with the next dose normally. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Pregabalina Tarbis
Do not stop taking Pregabalina unless your doctor tells you to. If you are going to stop treatment, this should be done gradually over a minimum of one week.
Once the treatment with Pregabalina is completed, whether short-term or long-term, you should know that you may experience certain adverse effects. These include insomnia, headaches, nausea, anxiety, diarrhea, flu-like symptoms, seizures, nervousness, depression, pain, sweating, and dizziness. These symptoms may appear more frequently or severely if you have been taking Pregabalina for a longer period.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
The very common side effects that may affect more than 1 in 10 people are:
The common side effects that may affect more than 1 in 100 people are:
The uncommon side effects that may affect more than 1 in 1,000 people are:
The rare side effects that may affect less than 1 in 1,000 people are:
If you experience swelling in the face or tongue, or if your skin becomes red and develops blisters or peeling, seek immediate medical attention.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging or in the bottle.The expiration date is the last day of the month indicated.
No special storage conditions are required
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of Pregabalina Tarbis
The active ingredient is pregabalina. Each hard capsule contains 300 mg of pregabalina.
The other components are: anhydrous calcium hydrogen phosphate (powder), anhydrous calcium hydrogen phosphate (granulated), croscarmellose sodium, talc. The capsule contains: gelatin, water, titanium dioxide (E-171), yellow iron oxide (E172), red iron oxide (E172)and printing ink composed of:Shellaclacquer, dehydrated alcohol,isopropyl alcohol, butyl alcohol, propylene glycol, concentrated ammonium solution, iron oxide black, potassium hydroxide, and purified water.
Appearance of the product and contents of the packaging
Pregabalina Tarbis 300 mg are hard gelatin capsules, pale pink and pale yellow in color, marked with “PGB” on the cap and “300” on the body. Pregabalina is available in packaging of 56 capsules and 100 capsules (clinical packaging) containing strips formed by PVC and an aluminum foil. Some packaging sizes may only be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Tarbis Farma, S.L.
Gran Vía Carlos III, 94
08028- Barcelona (Spain)
Responsible for manufacturing
Ferrer Internacional, S.A.
Joan Buscallà, 1-9
08173-Sant Cugat del Vallès (Barcelona)
(Spain)
Last review date of this leaflet: December 2016
The detailed information of this medicine is available on the website of theSpanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.